Recovery & Tissue Repair · Reviewed by Ian K. Tseng, MD

What Is BPC-157? The Pentadecapeptide, Explained

BPC-157 is one of the most searched compounds in the peptide space, and one of the most confidently discussed by people citing research they have not read. The mechanism is genuinely interesting, the evidence base is thinner than the internet suggests, and the regulatory picture changed substantially in 2026. Here is the honest version of all three.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Amber pharmacy vial labelled BPC-157 on warm marble, illustrating a recovery & tissue repair compound discussed in this educational article

Educational reference only

This page explains what this compound is and what the research shows. It is not an offer, a recommendation, or a statement about any particular clinic's formulary. Whether any therapy is appropriate for you is a decision a licensed physician makes after an individual evaluation.

The short answer

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — corresponding to a partial sequence identified in human gastric juice. Research has examined effects on tendon, ligament, muscle, and gastrointestinal tissue repair, predominantly in animal models. It is not FDA-approved, and under current federal rules it is not available through 503A compounding pharmacies: it was removed from the FDA’s Category 2 list in April 2026 but has not been added to the 503A bulks list.

What the compound is

BPC stands for "Body Protection Compound." The peptide is a synthetic fifteen-amino-acid sequence corresponding to a portion of a protein identified in human gastric juice. The original research interest came from the observation that the gastrointestinal tract maintains a remarkable capacity for self-repair in a chemically hostile environment, and the question of what mediates that.

Proposed mechanisms in the literature include effects on angiogenesis — the formation of new blood vessels — modulation of growth factor expression, and interaction with nitric oxide signaling pathways. These are plausible and interesting mechanisms.

What the evidence actually consists of

This is where careful reading matters. The substantial majority of published BPC-157 research is preclinical: rodent models, isolated tissue preparations, and in vitro work. The findings in those models are frequently striking, which is a large part of why the compound developed the reputation it has.

Well-controlled human clinical trials establishing efficacy and safety for the uses discussed online are, at the time of writing, largely absent. That is not a claim that the compound does nothing. It is a statement about the state of the evidence: animal data is a reason to investigate further, not a substitute for human trials. Many compounds with impressive rodent results have not replicated in humans.

Anyone presenting BPC-157 as an established, evidence-backed therapy for human tissue repair is describing a body of research that does not currently exist in that form.

BPC-157 — where the evidence comes from

Preclinical: animal models, isolated tissue, in vitroMost of the literature

Rodent models, isolated tissue preparations and in vitro work examining tendon, ligament, muscle and gastrointestinal healing. Findings are frequently striking, which is much of why the compound has the reputation it does.

Controlled human clinical trialsLimited

Well-controlled human trials establishing efficacy and safety for the uses discussed online are limited. Anyone describing BPC-157 as an established, evidence-backed therapy is overstating what exists.

Proportions are illustrative of the balance of published work, not a count of papers. Animal data is a reason to investigate further, not a substitute for human trials.

A regulatory status that moved in 2026

BPC-157's compounding status has changed materially, and much of what is written online predates the change. The timeline is worth stating precisely.

In 2023 the FDA placed BPC-157 in Category 2 of the 503A Bulks List — the designation for substances raising significant safety risks — citing limited safety data and insufficient characterization. For roughly two and a half years, that placement was the reason legitimate compounding pharmacies would not prepare it.

On April 22, 2026 the FDA removed BPC-157, along with eleven other peptides, from Category 2. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted to recommend BPC-157 for inclusion on the 503A Bulks List, by a margin of 8 to 6 with one abstention.

One clarification matters and is frequently glossed over: a PCAC recommendation is advisory, not binding. Formal inclusion on the bulks list requires FDA notice-and-comment rulemaking, which typically takes a year or more, and the agency has departed from committee recommendations before. The accurate description of BPC-157 today: not FDA-approved, no longer in the FDA's significant-safety-risk category, and carrying a favorable advisory recommendation with final rulemaking still pending. Until that rulemaking adds it to the bulks list, there is no pathway for 503A pharmacies to compound it.

BPC-157 — FDA compounding status

2023restricted
Placed in Category 2 of the 503A Bulks List
The designation for substances raising significant safety risks. Compounding pharmacies would not prepare it.
22 April 2026removed
Removed from Category 2
BPC-157 and eleven other peptides taken out of the significant-safety-risk category.
23 July 2026recommended
PCAC voted to recommend it for the Bulks List
Pharmacy Compounding Advisory Committee, 8 to 6 with one abstention. Advisory only.
Pendingnot final
FDA notice-and-comment rulemaking
Formal inclusion requires rulemaking, typically a year or more. The agency can depart from committee recommendations.

A committee recommendation is not a rule. Today the compound is not FDA-approved, rulemaking has not concluded, and there is no current 503A compounding pathway.

Not approved, and not currently compoundable

BPC-157 has not been through FDA pre-market review, and it does not carry an approved label, an approved indication, or approved dosing guidance. Removal from Category 2 did not by itself make it eligible for compounding: a 503A pharmacy generally needs a bulk substance to be on the bulks list, and BPC-157 is not on it yet. Until that changes, BPC-157 is not available through 503A compounding pharmacies under federal rules.

That also means BPC-157 offered for sale today is coming from outside the licensed pharmacy framework, which is the subject of the next section.

What the gray market is actually selling

BPC-157 is easy to buy online from vendors operating outside the prescription framework, under a "for research use only" or "not for human consumption" label. That labeling is the legal position that permits the sale — it is not a formality.

What arrives is a vial with no prescription, no physician evaluation, no purity standard verified for human administration, no dosing guidance grounded in human data, and no one accountable for an adverse reaction. Knowing the contents of the bottle says nothing about whether your body should receive them.

We covered this distinction at length in are peptides safe? It is the clearest line between a medical program and a research-chemical purchase, and it holds regardless of what the compounding status happens to be in any given year.

Why this article gives no dosing

BPC-157 is not an approved drug and is not currently compoundable under 503A, so there is no approved label or dosing guidance to cite, and we do not describe protocols or doses for it. For safety context: the proposed mechanisms are pro-angiogenic and pro-repair, which is why active or prior malignancy, pregnancy, and breastfeeding are the exclusions most often cited in the literature.

Frequently asked questions

Is BPC-157 legal?

Its status changed in 2026 and much of what is written online predates the change. The FDA placed BPC-157 in Category 2 of the 503A Bulks List in 2023, then removed it from that category on April 22, 2026. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 with one abstention to recommend it for inclusion on the bulks list. That recommendation is advisory — formal inclusion requires FDA notice-and-comment rulemaking, which is still pending. BPC-157 today is not FDA-approved, and until it is added to the bulks list there is no pathway for 503A pharmacies to compound it.

What does the BPC-157 research actually show?

The substantial majority of published research is preclinical — rodent models, isolated tissue preparations, and in vitro work — examining effects on tendon, ligament, muscle, and gastrointestinal healing, with proposed mechanisms involving angiogenesis, growth factor expression, and nitric oxide signaling. Well-controlled human clinical trials are limited. Animal data is a reason to investigate further, not a substitute for human trials, and anyone describing BPC-157 as an established evidence-backed therapy is overstating what exists.

Who should not take BPC-157?

Active malignancy or a history of it is the clearest exclusion — the proposed mechanisms are pro-angiogenic and pro-repair, which is the wrong signal in the presence of cancer. Pregnancy and breastfeeding are also exclusions. Baseline bloodwork including a comprehensive metabolic panel, confirmation of the indication, and verification that standard diagnostic evaluation is not being bypassed are standard parts of any physician evaluation before a repair-signalling therapy.

Vendors sell BPC-157 online. How is that different?

They label it "for research use only" or "not for human consumption," which is the legal position that permits sale outside the prescription framework. What arrives has no prescription, no physician evaluation, no purity standard verified for human administration, no dosing guidance grounded in human data, and no accountability for adverse reactions. Knowing the contents of the vial says nothing about whether your body should receive them.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Sikiric P, Rucman R, Turkovic B, et al. Novel Cytoprotective Mediator Stable Gastric Pentadecapeptide BPC 157. Current Pharmaceutical Design. 2018. pubmed.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. www.fda.gov
U.S. Food & Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. www.fda.gov

Explore our telehealth programs

Our telehealth wellness programs start with an intake and an evaluation by a clinician licensed in your state, with ongoing oversight from our licensed medical team, directed by Medical Director Ian K. Tseng, MD. What is clinically appropriate depends entirely on that evaluation, and not everyone qualifies. Available in 47 states + D.C.

See our programs

Serving Orange County, Los Angeles, and San Diego — plus telehealth in 47 states + D.C. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available via telehealth in 47 states and Washington, D.C. (every state except Alabama, Alaska and Mississippi); prescriptions are issued by clinicians licensed in your state.